Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer

We aimed to determine the maximum-tolerated dose (MTD) clinical toxicities, pharmacokinetics, and pharmacodynamics of oral JM216 given once daily for 5 days to cancer patients. Patients who fulfilled standard phase I trial criteria were enrolled. Oral JM216 was given at doses based on patient body-s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology Jg. 15; H. 7; S. 2691
Hauptverfasser:	McKeage, M J, Raynaud, F, Ward, J, Berry, C, O'Dell, D, Kelland, L R, Murrer, B, Santabárabara, P, Harrap, K R, Judson, I R
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.07.1997
Schlagworte:	Administration, Oral Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Area Under Curve Drug Administration Schedule Female Gastrointestinal Diseases - chemically induced Hematologic Diseases - chemically induced Humans Male Middle Aged Neoplasms - blood Neoplasms - drug therapy Organoplatinum Compounds Severity of Illness Index Ultrafiltration
ISSN:	0732-183X
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!